NCT06178718View on ClinicalTrials.gov

A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 6, 2016

Primary Completion Date

August 2, 2016

Study Completion Date

August 2, 2016

Conditions
Hyperammonemia
Interventions
DRUG

TNP-2092 capsules

Administered orally, 100 to 1200 mg

DRUG

TNP-2092 placebo capsules

Administered orally

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

lead

TenNor Therapeutics (Suzhou) Limited

INDUSTRY

NCT06178718 - A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules | Biotech Hunter | Biotech Hunter